



0360

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Michel Pairet et al) Art Unit: to be assigned
Serial No. : 10/086,145) Examiner: to be assigned
Filed : October 19, 2001) Docket No.: 1/1174
For : Pharmaceutical Compositions Based on Anticholinergics and
Corticosteroids

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement under 37 C.F.R. §§1.56 and

☒ 1.97(b). This Statement is being filed within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; or before the mailing of a first Office Action on the merits, whichever event occurs last.

☒ The Assistant Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

The references cited on the enclosed Form 1449A/PTO are not conceded to be prior art.

Triplicate copies of this form are enclosed.

Respectfully submitted,

Timothy X. Witkowski
Attorney for Applicant(s)
Reg. No. 40,232


Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road
P.O. Box 368
Ridgefield, CT 06877
Tel.: (203) 798-4310
Docket No.: 1/1174

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, DC 20231

on April 1, 2001

By: Timothy X. Witkowski
Reg. No. 40,232



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

1

Complete if Known

Application Number	10/086,145
Filing Date	October 19, 2001
First Named Inventor	Michel Pairet
Art Unit	to be assigned
Examiner Name	to be assigned
Attorney Docket Number	1/1174

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number- Kind Code ² (if known)			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
		WO-01/78736-A1	10/25/2001	Galxo Group Limited		
		WO-01/78739-A1	10/25/2001	Glaxo Group Limited		
		WO-01/78741-A1	10/25/2001	Glaxo Group Limited		
		WO-01/78743-A1	10/25/2001	Glaxo Group Limited		

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.